The Medicare Evidence Development & Coverage Advisory Committee should mandate outcomes data collection and analyze patient results.
CMS should review the FDA’s Alzheimer drug decision
CMS should review the FDA’s Alzheimer drug…
CMS should review the FDA’s Alzheimer drug decision
The Medicare Evidence Development & Coverage Advisory Committee should mandate outcomes data collection and analyze patient results.